Tech Support

TECHNICAL SUPPORT
+1.800.674.3430

This line is for technical support.
For General Enquiries please click General Contact

Multiple Sclerosis

In vivo preclinical models capturing key MS clinical and pathologic features
inflammaiton-magnifyglass

Progress your MS Agent Program with our Well-Characterized Preclinical Models

Utilize preclinical models of experimental autoimmune encephalomyelitis (EAE) to evaluate agent efficacy in a clinically and pathologically relevant setting.

  • Myelin oligodendrocyte glycoprotein-induced experimental autoimmune encephalomyelitis (MOG-EAE) model
  • Proteolipid protein-induced experimental autoimmune encephalomyelitis (PLP-EAE) relapsing-remitting model coming soon

MOG-EAE Model

Mice are immunized with MOG35-55 myelin-associated peptide in complete Freunds adjuvant to trigger immune response, then treated with pertussis toxin to promote increased transport of leukocytes across the blood-brain barrier. Disease onset occurs after Day 10.

Major Endpoints

  • Weight loss
  • Disease paralysis score
  • Cytokine levels
  • FACS analysis of immune cell populations
  • Histopathology assessment of brain and spinal cord
MOG-EAE Model Validation with FTY-720 (Fingolimod)


Figure 1: MOG-EAE Model Validation with FTY-720 (Fingolimod)

MOG-EAE Mouse Model Representative Spinal Cord Histopathology


Figure 2: MOG-EAE Mouse Model Representative Spinal Cord Histopathology